Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial

Area of Science:

• Sleep Medicine
• Neurology
• Pharmacology

Background:

• Obstructive sleep apnea (OSA) patients intolerant of standard treatments have limited options.
• Daytime impairment may persist despite weight loss efforts in OSA patients.

Purpose of the Study:

• To evaluate if armodafinil improves driving performance in overweight adults with OSA undergoing weight loss.
• To assess armodafinil's effect on daytime sleepiness and body composition in this patient group.

Main Methods:

• A 6-month, placebo-controlled, double-blind, randomized trial involving overweight adults with OSA and daytime sleepiness.
• Participants received either armodafinil or placebo daily, alongside one of two assigned diets.
• Driving task performance, Epworth Sleepiness Scale, and body composition were primary and secondary outcomes.

Main Results:

• Armodafinil improved driving performance at 3 months but not at the primary 6-month endpoint.
• Patients receiving armodafinil experienced significantly greater fat mass reduction (2.4 kg more than placebo).
• No significant improvements were observed in other secondary outcomes like Epworth Sleepiness Scale scores.

Conclusions:

• Armodafinil did not meet the primary endpoint for improving driving performance at 6 months in OSA patients undergoing weight loss.
• The drug may offer benefits as an adjunct to weight loss for OSA patients who cannot tolerate conventional therapies.
• Further research in a specifically designed, adequately powered clinical trial is warranted to confirm these findings.